Sector Gamma AS Acquires 22,943 Shares of Elevance Health, Inc. $ELV

Sector Gamma AS increased its holdings in Elevance Health, Inc. (NYSE:ELV) by 238.9% in the 4th quarter, Holdings Channel reports. The institutional investor owned 32,546 shares of the company’s stock after purchasing an additional 22,943 shares during the period. Elevance Health accounts for 2.6% of Sector Gamma AS’s investment portfolio, making the stock its 17th largest holding. Sector Gamma AS’s holdings in Elevance Health were worth $11,409,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Rossby Financial LCC lifted its holdings in shares of Elevance Health by 110.0% during the 3rd quarter. Rossby Financial LCC now owns 84 shares of the company’s stock worth $28,000 after acquiring an additional 44 shares during the last quarter. J.Safra Asset Management Corp bought a new stake in shares of Elevance Health during the 4th quarter worth $32,000. ORG Partners LLC lifted its holdings in shares of Elevance Health by 120.4% during the 4th quarter. ORG Partners LLC now owns 108 shares of the company’s stock worth $38,000 after acquiring an additional 59 shares during the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new stake in shares of Elevance Health during the 4th quarter worth $38,000. Finally, Dorato Capital Management bought a new stake in shares of Elevance Health during the 4th quarter worth $41,000. 89.24% of the stock is owned by institutional investors.

Elevance Health Price Performance

Shares of NYSE ELV opened at $399.64 on Friday. Elevance Health, Inc. has a 1 year low of $273.71 and a 1 year high of $426.98. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.48. The company’s 50-day moving average is $364.53 and its 200 day moving average is $344.44. The stock has a market capitalization of $86.79 billion, a P/E ratio of 17.00, a P/E/G ratio of 2.29 and a beta of 0.67.

Elevance Health (NYSE:ELV) last announced its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.74 by $1.84. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The company had revenue of $49.49 billion for the quarter, compared to analysts’ expectations of $48.21 billion. During the same quarter in the previous year, the company earned $11.97 earnings per share. Elevance Health’s quarterly revenue was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, sell-side analysts expect that Elevance Health, Inc. will post 26.93 earnings per share for the current year.

Elevance Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be given a dividend of $1.72 per share. The ex-dividend date is Wednesday, June 10th. This represents a $6.88 annualized dividend and a dividend yield of 1.7%. Elevance Health’s payout ratio is currently 29.26%.

Analysts Set New Price Targets

ELV has been the subject of several recent research reports. Truist Financial boosted their price target on shares of Elevance Health from $375.00 to $450.00 and gave the stock a “buy” rating in a research note on Monday, June 1st. Deutsche Bank Aktiengesellschaft upgraded shares of Elevance Health from a “hold” rating to a “buy” rating and boosted their price objective for the company from $363.00 to $498.00 in a research report on Wednesday, May 20th. UBS Group boosted their price objective on shares of Elevance Health from $400.00 to $460.00 and gave the company a “buy” rating in a research report on Friday, May 22nd. Morgan Stanley boosted their price objective on shares of Elevance Health from $352.00 to $404.00 and gave the company an “equal weight” rating in a research report on Thursday, June 4th. Finally, Bank of America boosted their price objective on shares of Elevance Health from $435.00 to $460.00 and gave the company a “buy” rating in a research report on Thursday, June 4th. Fourteen investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $416.11.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.